Scientific Reports 7:8273; doi:10.1038/s41598-017-07921-2; Article published online 15 August 2017
The original version of this Article omitted an affiliation for Ming Zhao. The correct affiliations for Ming Zhao are listed below:
Runliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Department of Public Health, Longsai Hospital, 315200, Ningbo, China.
This has now been corrected in the HTML and PDF versions of this Article, and in the accompanying Supplemental Material.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The original article can be found online at ..https://doi.org/10.1038/s41598-017-07921-2.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhao, M., Chen, J., Yuan, Y. et al. Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep 7, 16558 (2017). https://doi.org/10.1038/s41598-017-16510-2
Published:
DOI: https://doi.org/10.1038/s41598-017-16510-2
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
